A compound of formula (I-1), or a pharmaceutically acceptable salt or hydrate thereof, wherein: ring A is a monocyclic 5, 6, or 7-membered heterocycloalkyl ring optionally substituted by one or more substituents selected from alkyl, CN, cycloalkyl, OH, alkoxy, halo, haloalkyl and heteroaryl, wherein said heteroaryl group is in turn optionally further substituted with one or more groups selected from halo and alkyl, and wherein one or two carbons in the 5, 6, or 7-membered heterocycloalkyl ring are optionally replaced by a group selected from O, NH, S and CO; L is a linker group which is a 2 to 7-membered saturated or unsaturated aliphatic group, wherein one or two carbon atoms in said group, other than the carbon atom directly bonded to ring A, are optionally replaced by a heteroatom-containing group selected from O, NH and S, and wherein when two carbon atoms are replaced, the heteroatom-containing groups are separated by at least two carbon atoms and the linker group is at least a 5-membered group; the group X-Y is -NR 23 SO 2 - or -SO 2 NR 23 -; R 1 is selected from H, CN and alkyl; R 2 is selected from COOH, tetrazolyl and C(O)NHSO 2 R 24 ; R 3 is selected from H, halo and alkyl; R 4 is selected from H and halo; R 6 is H; R 7 is selected from H, CN, haloalkyl, halo, SO 2 -alkyl, SO 2 NR 18 R 19 , CONR 20 R 21 , heteroaryl and alkyl, wherein said heteroaryl group is optionally substituted by one or more substituents selected from alkyl, halo, alkoxy, CN, haloalkyl and OH; R 8 is selected from H, alkyl, haloalkyl and halo; R 9 is selected from H, alkyl and halo; R 18 -R 21 and R 23 are each independently selected from H and alkyl; and R 24 is selected from alkyl and cyclopropyl. ring A is a monocyclic 5, 6, or 7-membered heterocycloalkyl ring optionally substituted by one or more substituents selected from alkyl, CN, cycloalkyl, OH, alkoxy, halo, haloalkyl and heteroaryl, wherein said heteroaryl group is in turn optionally further substituted with one or more groups selected from halo and alkyl, and wherein one or two carbons in the 5, 6, or 7-membered heterocycloalkyl ring are optionally replaced by a group selected from O, NH, S and CO; L is a linker group which is a 2 to 7-membered saturated or unsaturated aliphatic group, wherein one or two carbon atoms in said group, other than the carbon atom directly bonded to ring A, are optionally replaced by a heteroatom-containing group selected from O, NH and S, and wherein when two carbon atoms are replaced, the heteroatom-containing groups are separated by at least two carbon atoms and the linker group is at least a 5-membered group; the group X-Y is -NR 23 SO 2 - or -SO 2 NR 23 -; R 1 is selected from H, CN and alkyl; R 2 is selected from COOH, tetrazolyl and C(O)NHSO 2 R 24 ; R 3 is selected from H, halo and alkyl; R 4 is selected from H and halo; R 6 is H; R 7 is selected from H, CN, haloalkyl, halo, SO 2 -alkyl, SO 2 NR 18 R 19 , CONR 20 R 21 , heteroaryl and alkyl, wherein said heteroaryl group is optionally substituted by one or more substituents selected from alkyl, halo, alkoxy, CN, haloalkyl and OH; R 8 is selected from H, alkyl, haloalkyl and halo; R 9 is selected from H, alkyl and halo; R 18 -R 21 and R 23 are each independently selected from H and alkyl; and R 24 is selected from alkyl and cyclopropyl. <EOS>